Benzinga | Feb 25, 2021 08:02AM EST

Intra-Cellular Therapies Q4 EPS $(0.76) Beats $(0.85) Estimate, Sales $12.45M Beat $11.84M Estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.85) by 10.59 percent. This is a 2.7 percent decrease over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $12.45 million which beat the analyst consensus estimate of $11.84 million by 5.19 percent. This is a 20.45K percent increase over sales of $60.61 thousand the same period last year.